IL208020A0 - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts - Google Patents

Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Info

Publication number
IL208020A0
IL208020A0 IL208020A IL20802010A IL208020A0 IL 208020 A0 IL208020 A0 IL 208020A0 IL 208020 A IL208020 A IL 208020A IL 20802010 A IL20802010 A IL 20802010A IL 208020 A0 IL208020 A0 IL 208020A0
Authority
IL
Israel
Prior art keywords
benzimidazol
methylpiperazin
quinolin
fluoro
amino
Prior art date
Application number
IL208020A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL208020(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL208020A0 publication Critical patent/IL208020A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL208020A 2008-03-19 2010-09-06 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts IL208020A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
IL208020A0 true IL208020A0 (en) 2010-12-30

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208020A IL208020A0 (en) 2008-03-19 2010-09-06 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Country Status (24)

Country Link
US (1) US8563556B2 (enExample)
EP (1) EP2257544B1 (enExample)
JP (1) JP2011515370A (enExample)
KR (1) KR20100137517A (enExample)
CN (1) CN101970425B (enExample)
AR (1) AR070924A1 (enExample)
AU (1) AU2009227003B2 (enExample)
BR (1) BRPI0909762A2 (enExample)
CA (1) CA2718076A1 (enExample)
CL (1) CL2009000651A1 (enExample)
CO (1) CO6321253A2 (enExample)
EC (1) ECSP10010555A (enExample)
IL (1) IL208020A0 (enExample)
MA (1) MA32230B1 (enExample)
MX (1) MX2010010152A (enExample)
MY (1) MY150554A (enExample)
NZ (2) NZ600887A (enExample)
PE (1) PE20091628A1 (enExample)
PH (2) PH12012502569A1 (enExample)
RU (1) RU2497820C2 (enExample)
SG (1) SG188919A1 (enExample)
TW (1) TWI426072B (enExample)
WO (1) WO2009115562A2 (enExample)
ZA (1) ZA201006263B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2011128405A1 (en) 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds
PL2558095T3 (pl) 2010-04-16 2019-06-28 Novartis Ag Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
AU2012229107A1 (en) 2011-03-17 2013-09-19 Novartis Ag FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
KR20140062485A (ko) 2011-09-15 2014-05-23 노파르티스 아게 중등도 간 손상 환자의 암 치료에 있어서 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온의 용도
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309996T1 (de) * 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
JP4890255B2 (ja) * 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
SG173317A1 (en) * 2005-01-27 2011-08-29 Novartis Vaccines & Diagnostic Treatment of metastasized tumors
AU2006249847B2 (en) * 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
NZ567550A (en) 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
AR070924A1 (es) 2010-05-12
US8563556B2 (en) 2013-10-22
EP2257544A2 (en) 2010-12-08
ZA201006263B (en) 2011-05-25
RU2010142396A (ru) 2012-04-27
CN101970425B (zh) 2014-04-16
MA32230B1 (fr) 2011-04-01
RU2497820C2 (ru) 2013-11-10
WO2009115562A2 (en) 2009-09-24
CL2009000651A1 (es) 2010-07-19
PH12012502568A1 (en) 2014-10-27
AU2009227003B2 (en) 2013-03-14
AU2009227003A1 (en) 2009-09-24
HK1147492A1 (en) 2011-08-12
CN101970425A (zh) 2011-02-09
KR20100137517A (ko) 2010-12-30
TWI426072B (zh) 2014-02-11
CO6321253A2 (es) 2011-09-20
MX2010010152A (es) 2010-10-25
BRPI0909762A2 (pt) 2018-04-03
ECSP10010555A (es) 2010-11-30
PH12012502569A1 (en) 2015-09-21
WO2009115562A3 (en) 2009-11-26
EP2257544B1 (en) 2014-12-03
CA2718076A1 (en) 2009-09-24
JP2011515370A (ja) 2011-05-19
US20110021536A1 (en) 2011-01-27
TW201000463A (en) 2010-01-01
SG188919A1 (en) 2013-04-30
NZ587829A (en) 2012-08-31
NZ600887A (en) 2013-10-25
MY150554A (en) 2014-01-30
PE20091628A1 (es) 2009-11-19

Similar Documents

Publication Publication Date Title
IL208020A0 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP2136824A4 (en) USE OF SELECTED MILKY ACID BACTERIA TO REDUCE ATHEROSCLEROSIS
ZA201107592B (en) Salt of abt-263 and solid-state forms thereof
PT2334295T (pt) Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
IL194779A0 (en) Use of selected lactic acid bacteria for reducing infantile colic
EP2311498A4 (en) EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF
IL206704A0 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
EP2094665A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
EP1988155A4 (en) LACTIC ACID BACTERIUM CAPABLE OF PRODUCING AMINO-ACUTE ACID
EP2619194A4 (en) CATECHIN FATTY ACID DERIVATIVES AND METHODS OF USE
EP2265586A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
PL2001862T3 (pl) Jabłczany oraz odmiany polimorficzne kwasu (3S,5S)-7-[3-amino-5-metylo-piperydynylo]-1-cyklopropylo-1,4-dihydro-8-metoksy-4-okso-3-chinolinokarboksylowego
IL219934A0 (en) Quinazolin-4(3a)-one derivatives and methods of use thereof
IT1395963B1 (it) Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
ZA201105542B (en) Cefdinir acid double salt and its preparation
TH0901001214A (th) รูปแบบที่เป็นผลึก และสองรูปแบบที่เป็นซอลเวทของเกลือ 4-อะมิโน-5-ฟลูออโร-3-[5-(4-เมทธิลพิเพอราซิน-1-อิล)-1h-เบนซิมิดาซอล-2-อิล]ควิโนลิน-2(1h)-โอน แลคติก แอซิด
IL215512A0 (en) Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
IL192554A0 (en) Controlled release formulation of divalproic acid and its derivatives
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
HK1109772A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
IL216782A0 (en) Solid states forms of varenicline salts and processes for preparation therrof
PL2128152T3 (pl) Proces oczyszczania cyklicznych diestrów kwasu L-lub D-mlekowego
HK40104059A (zh) 来那替尼马来酸盐及晶形

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees